Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 28:10.1002/jmv.28157. Online ahead of print. doi: 10.1002/jmv.28157

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Wiley Periodicals LLC.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Effects of gilteritinib, nintedanib, and imatinib on phospholipidosis (PLD) in ACE2‐A549 cells. Comparison of induction of PLD by gilteritinib, nintedanib, and imatinib versus the positive control amodiaquine. Cells were pretreated with NBD‐PE reagent for 2 h before compound addition. Compounds were added in dose curves and cells were incubated overnight. PLD was quantified using Cell Profiler to measure NBD‐PE signal intensity per nuclei, and values were normalized to the negative control DMSO. EC50 values were calculated in Prism using a variable‐slope four‐parameter model.